This Article Full Text Full Text (PDF) All Versions of this Article: 23/1/111    most recent 01.ATV.0000047460.27435.B8v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hegele, R. A. Articles by Cao, H. Search for Related Content PubMed PubMed Citation Articles by Hegele, R. A. Articles by Cao, H. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Genetics Home Reference Related Collections Clinical genetics Genetics of cardiovascular disease Lipid and lipoprotein metabolism Glucose intolerance Risk Factors

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:111.)
© 2003 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Elevated Serum C-Reactive Protein and Free Fatty Acids Among Nondiabetic Carriers of Missense Mutations in the Gene Encoding Lamin A/C (LMNA) With Partial Lipodystrophy

Robert A. Hegele; Maria E. Kraw; Matthew R. Ban; Brooke A. Miskie; Murray W. Huff; Henian Cao

From the Blackburn Cardiovascular Genetics Laboratory and Vascular Biology Research Group, Robarts Research Institute, London, Ontario, Canada.

Correspondence to Robert A. Hegele, MD, FRCPC, FACP, Blackburn Cardiovascular Genetics Laboratory, Robarts Research Institute, 406-100 Perth Dr, London, Ontario, Canada N6A 5K8. E-mail hegele{at}robarts.com

Objective— Dunnigan-type familial partial lipodystrophy (FPLD) due to mutant LMNA is a monogenic form of insulin resistance. Affected subjects, especially women, are at increased risk of early coronary heart disease (CHD). Although common insulin resistance is associated with several biochemical perturbations, including elevated C-reactive protein (CRP), the biochemical profile in subjects with mutant LMNA is incompletely defined.

Methods and Results— We studied 35 nondiabetic adult FPLD subjects (of whom 24 were women) with either the LMNA R482Q or R482W missense mutations and 51 matched normal first-degree relatives (of whom 27 were women). Compared with normal controls, LMNA mutation carriers had significantly higher plasma insulin and more dyslipidemia, higher mean triglycerides and lower HDL cholesterol, significantly higher nonesterified free fatty acids and CRP, and significantly lower leptin and adiponectin than controls. Subgroup analyses showed that these differences were more pronounced in women. Other biomarkers such as resistin, fibrinogen, and plasminogen activator inhibitor-1 were not different between groups.

Conclusions— LMNA mutations in nondiabetic patients with FPLD are associated with several metabolic and biochemical changes, particularly in women. The unfavorable profile might contribute to the increased susceptibility to CHD seen in LMNA mutation carriers.

Key Words: insulin resistance • diabetes • DNA analysis • cytokines • risk factor

This article has been cited by other articles:

				A. Megia, J. Vendrell, C. Gutierrez, M. Sabate, M. Broch, J.-M. Fernandez-Real, and I. Simon Insulin sensitivity and resistin levels in gestational diabetes mellitus and after parturition Eur. J. Endocrinol., February 1, 2008; 158(2): 173 - 178. [Abstract] [Full Text] [PDF]

				L. A. Kosmiski, P. Bacchetti, D. P. Kotler, S. B. Heymsfield, C. E. Lewis, M. G. Shlipak, R. Scherzer, and C. Grunfeld Relationship of Fat Distribution with Adipokines in Human Immunodeficiency Virus Infection J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 216 - 224. [Abstract] [Full Text] [PDF]

				A. Ludtke, J. Buettner, W. Wu, A. Muchir, A. Schroeter, S. Zinn-Justin, S. Spuler, H. H.-J. Schmidt, and H. J. Worman Peroxisome Proliferator-Activated Receptor-{gamma} C190S Mutation Causes Partial Lipodystrophy J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2248 - 2255. [Abstract] [Full Text] [PDF]

				C. Power, S. K. Miller, and P. T. Alpert Promising New Causal Explanations for Obesity and Obesity-Related Diseases Biol Res Nurs, January 1, 2007; 8(3): 223 - 233. [Abstract] [PDF]

				M. J. Bahr, J. Ockenga, K. H. W. Boker, M. P. Manns, and U. J. F. Tietge Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E199 - E206. [Abstract] [Full Text] [PDF]

				R. A. Hegele and R. L. Pollex Genetic and physiological insights into the metabolic syndrome Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2005; 289(3): R663 - R669. [Abstract] [Full Text] [PDF]

				M. P. Reilly, M. Lehrke, M. L. Wolfe, A. Rohatgi, M. A. Lazar, and D. J. Rader Resistin Is an Inflammatory Marker of Atherosclerosis in Humans Circulation, February 22, 2005; 111(7): 932 - 939. [Abstract] [Full Text] [PDF]

				M. C. Vantyghem, P. Pigny, C. A. Maurage, N. Rouaix-Emery, T. Stojkovic, J. M. Cuisset, A. Millaire, O. Lascols, P. Vermersch, J. L. Wemeau, et al. Patients with Familial Partial Lipodystrophy of the Dunnigan Type Due to a LMNA R482W Mutation Show Muscular and Cardiac Abnormalities J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5337 - 5346. [Abstract] [Full Text] [PDF]

				K. Z. Al-Shali and R. A. Hegele Laminopathies and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., September 1, 2004; 24(9): 1591 - 1595. [Abstract] [Full Text] [PDF]

				B. Vozarova de Courten, M. Degawa-Yamauchi, R. V. Considine, and P. A. Tataranni High Serum Resistin Is Associated With an Increase in Adiposity But Not a Worsening of Insulin Resistance in Pima Indians Diabetes, May 1, 2004; 53(5): 1279 - 1284. [Abstract] [Full Text] [PDF]

				J. H. Lee, J. L. Chan, N. Yiannakouris, M. Kontogianni, E. Estrada, R. Seip, C. Orlova, and C. S. Mantzoros Circulating Resistin Levels Are Not Associated with Obesity or Insulin Resistance in Humans and Are Not Regulated by Fasting or Leptin Administration: Cross-Sectional and Interventional Studies in Normal, Insulin-Resistant, and Diabetic Subjects J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4848 - 4856. [Abstract] [Full Text] [PDF]

				M. Lean Is there a metabolic rationale to support a weight loss programme to prevent diabetes? The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1_suppl): S12 - S17. [Abstract] [PDF]